NCCN GUIDELINES® INSIGHTS: Central Nervous System Cancers, Version 2.2022

Craig Horbinski; Louis Burt Nabors; Jana Portnow; Joachim Baehring; Ankush Bhatia; Orin Bloch; Steven Brem; Nicholas Butowski; Donald M. Cannon; Samuel Chao; Milan G. Chheda; Andrew J. Fabiano; Peter Forsyth; Pierre Gigilio; Jona Hattangadi-Gluth; Matthias Holdhoff; Larry Junck; Thomas Kaley; Ryan Merrell; Maciej M. Mrugala; Seema Nagpal; Lucien A. Nedzi; Kathryn Nevel; Phioanh L. Nghiemphu; Ian Parney; Toral R. Patel; Katherine Peters; Vinay K. Puduvalli; Jason Rockhill; Chad Rusthoven; Nicole Shonka; Lode J. Swinnen; Stephanie Weiss; Patrick Yung Wen; Nicole E. Willmarth; Mary Anne Bergman; Susan Darlow

doi:10.6004/jnccn.2023.0002

NCCN GUIDELINES^® INSIGHTS: Central Nervous System Cancers, Version 2.2022

Craig Horbinski, Louis Burt Nabors, Jana Portnow, Joachim Baehring, Ankush Bhatia, Orin Bloch, Steven Brem, Nicholas Butowski, Donald M. Cannon, Samuel Chao, Milan G. Chheda, Andrew J. Fabiano, Peter Forsyth, Pierre Gigilio, Jona Hattangadi-Gluth, Matthias Holdhoff, Larry Junck, Thomas Kaley, Ryan Merrell, Maciej M. MrugalaSeema Nagpal, Lucien A. Nedzi, Kathryn Nevel, Phioanh L. Nghiemphu, Ian Parney, Toral R. Patel, Katherine Peters, Vinay K. Puduvalli, Jason Rockhill, Chad Rusthoven, Nicole Shonka, Lode J. Swinnen, Stephanie Weiss, Patrick Yung Wen, Nicole E. Willmarth, Mary Anne Bergman, Susan Darlow

Research output: Contribution to journal › Article › peer-review

64 Scopus citations

Abstract

The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of the following adult CNS cancers: glioma (WHO grade 1, WHO grade 2–3 oligodendroglioma [1p19q codeleted, IDH-mutant], WHO grade 2–4 IDH-mutant astrocytoma, WHO grade 4 glioblastoma), intracranial and spinal ependymomas, medulloblastoma, limited and extensive brain metastases, leptomeningeal metastases, non–AIDS-related primary CNS lymphomas, metastatic spine tumors, meningiomas, and primary spinal cord tumors. The information contained in the algorithms and principles of management sections in the NCCN Guidelines for CNS Cancers are designed to help clinicians navigate through the complex management of patients with CNS tumors. Several important principles guide surgical management and treatment with radiotherapy and systemic therapy for adults with brain tumors. The NCCN CNS Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding molecular profiling of gliomas.

Original language	English (US)
Pages (from-to)	12-20
Number of pages	9
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	21
Issue number	1
DOIs	https://doi.org/10.6004/jnccn.2023.0002
State	Published - Jan 2023

Funding

This activity is supported by educational grants from AstraZeneca; Exact Sciences; Novartis; and Taiho Oncology, Inc. This activity is supported by an independent educational grant from Daiichi Sankyo. This activity is supported by independent medical education grants from Illumina, Inc. and Regeneron Pharmaceuticals, Inc.

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.6004/jnccn.2023.0002

Cite this

Horbinski, C., Nabors, L. B., Portnow, J., Baehring, J., Bhatia, A., Bloch, O., Brem, S., Butowski, N., Cannon, D. M., Chao, S., Chheda, M. G., Fabiano, A. J., Forsyth, P., Gigilio, P., Hattangadi-Gluth, J., Holdhoff, M., Junck, L., Kaley, T., Merrell, R., ... Darlow, S. (2023). NCCN GUIDELINES^® INSIGHTS: Central Nervous System Cancers, Version 2.2022. JNCCN Journal of the National Comprehensive Cancer Network, 21(1), 12-20. https://doi.org/10.6004/jnccn.2023.0002

@article{334d4e8188fe43b08de75121ac049782,

title = "NCCN GUIDELINES{\textregistered} INSIGHTS: Central Nervous System Cancers, Version 2.2022",

abstract = "The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of the following adult CNS cancers: glioma (WHO grade 1, WHO grade 2–3 oligodendroglioma [1p19q codeleted, IDH-mutant], WHO grade 2–4 IDH-mutant astrocytoma, WHO grade 4 glioblastoma), intracranial and spinal ependymomas, medulloblastoma, limited and extensive brain metastases, leptomeningeal metastases, non–AIDS-related primary CNS lymphomas, metastatic spine tumors, meningiomas, and primary spinal cord tumors. The information contained in the algorithms and principles of management sections in the NCCN Guidelines for CNS Cancers are designed to help clinicians navigate through the complex management of patients with CNS tumors. Several important principles guide surgical management and treatment with radiotherapy and systemic therapy for adults with brain tumors. The NCCN CNS Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel{\textquoteright}s most recent recommendations regarding molecular profiling of gliomas.",

author = "Craig Horbinski and Nabors, {Louis Burt} and Jana Portnow and Joachim Baehring and Ankush Bhatia and Orin Bloch and Steven Brem and Nicholas Butowski and Cannon, {Donald M.} and Samuel Chao and Chheda, {Milan G.} and Fabiano, {Andrew J.} and Peter Forsyth and Pierre Gigilio and Jona Hattangadi-Gluth and Matthias Holdhoff and Larry Junck and Thomas Kaley and Ryan Merrell and Mrugala, {Maciej M.} and Seema Nagpal and Nedzi, {Lucien A.} and Kathryn Nevel and Nghiemphu, {Phioanh L.} and Ian Parney and Patel, {Toral R.} and Katherine Peters and Puduvalli, {Vinay K.} and Jason Rockhill and Chad Rusthoven and Nicole Shonka and Swinnen, {Lode J.} and Stephanie Weiss and Wen, {Patrick Yung} and Willmarth, {Nicole E.} and Bergman, {Mary Anne} and Susan Darlow",

note = "Funding Information: This activity is supported by educational grants from AstraZeneca; Exact Sciences; Novartis; and Taiho Oncology, Inc. This activity is supported by an independent educational grant from Daiichi Sankyo. This activity is supported by independent medical education grants from Illumina, Inc. and Regeneron Pharmaceuticals, Inc. Publisher Copyright: {\textcopyright} 2023 National Comprehensive Cancer Network{\textregistered} (NCCN{\textregistered}), All rights reserved.",

year = "2023",

month = jan,

doi = "10.6004/jnccn.2023.0002",

language = "English (US)",

volume = "21",

pages = "12--20",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "1",

}

Horbinski, C, Nabors, LB, Portnow, J, Baehring, J, Bhatia, A, Bloch, O, Brem, S, Butowski, N, Cannon, DM, Chao, S, Chheda, MG, Fabiano, AJ, Forsyth, P, Gigilio, P, Hattangadi-Gluth, J, Holdhoff, M, Junck, L, Kaley, T, Merrell, R, Mrugala, MM, Nagpal, S, Nedzi, LA, Nevel, K, Nghiemphu, PL, Parney, I, Patel, TR, Peters, K, Puduvalli, VK, Rockhill, J, Rusthoven, C, Shonka, N, Swinnen, LJ, Weiss, S, Wen, PY, Willmarth, NE, Bergman, MA & Darlow, S 2023, 'NCCN GUIDELINES^® INSIGHTS: Central Nervous System Cancers, Version 2.2022', JNCCN Journal of the National Comprehensive Cancer Network, vol. 21, no. 1, pp. 12-20. https://doi.org/10.6004/jnccn.2023.0002

TY - JOUR

T1 - NCCN GUIDELINES® INSIGHTS

T2 - Central Nervous System Cancers, Version 2.2022

AU - Horbinski, Craig

AU - Nabors, Louis Burt

AU - Portnow, Jana

AU - Baehring, Joachim

AU - Bhatia, Ankush

AU - Bloch, Orin

AU - Brem, Steven

AU - Butowski, Nicholas

AU - Cannon, Donald M.

AU - Chao, Samuel

AU - Chheda, Milan G.

AU - Fabiano, Andrew J.

AU - Forsyth, Peter

AU - Gigilio, Pierre

AU - Hattangadi-Gluth, Jona

AU - Holdhoff, Matthias

AU - Junck, Larry

AU - Kaley, Thomas

AU - Merrell, Ryan

AU - Mrugala, Maciej M.

AU - Nagpal, Seema

AU - Nedzi, Lucien A.

AU - Nevel, Kathryn

AU - Nghiemphu, Phioanh L.

AU - Parney, Ian

AU - Patel, Toral R.

AU - Peters, Katherine

AU - Puduvalli, Vinay K.

AU - Rockhill, Jason

AU - Rusthoven, Chad

AU - Shonka, Nicole

AU - Swinnen, Lode J.

AU - Weiss, Stephanie

AU - Wen, Patrick Yung

AU - Willmarth, Nicole E.

AU - Bergman, Mary Anne

AU - Darlow, Susan

N1 - Funding Information: This activity is supported by educational grants from AstraZeneca; Exact Sciences; Novartis; and Taiho Oncology, Inc. This activity is supported by an independent educational grant from Daiichi Sankyo. This activity is supported by independent medical education grants from Illumina, Inc. and Regeneron Pharmaceuticals, Inc. Publisher Copyright: © 2023 National Comprehensive Cancer Network® (NCCN®), All rights reserved.

PY - 2023/1

Y1 - 2023/1

N2 - The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of the following adult CNS cancers: glioma (WHO grade 1, WHO grade 2–3 oligodendroglioma [1p19q codeleted, IDH-mutant], WHO grade 2–4 IDH-mutant astrocytoma, WHO grade 4 glioblastoma), intracranial and spinal ependymomas, medulloblastoma, limited and extensive brain metastases, leptomeningeal metastases, non–AIDS-related primary CNS lymphomas, metastatic spine tumors, meningiomas, and primary spinal cord tumors. The information contained in the algorithms and principles of management sections in the NCCN Guidelines for CNS Cancers are designed to help clinicians navigate through the complex management of patients with CNS tumors. Several important principles guide surgical management and treatment with radiotherapy and systemic therapy for adults with brain tumors. The NCCN CNS Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding molecular profiling of gliomas.

AB - The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of the following adult CNS cancers: glioma (WHO grade 1, WHO grade 2–3 oligodendroglioma [1p19q codeleted, IDH-mutant], WHO grade 2–4 IDH-mutant astrocytoma, WHO grade 4 glioblastoma), intracranial and spinal ependymomas, medulloblastoma, limited and extensive brain metastases, leptomeningeal metastases, non–AIDS-related primary CNS lymphomas, metastatic spine tumors, meningiomas, and primary spinal cord tumors. The information contained in the algorithms and principles of management sections in the NCCN Guidelines for CNS Cancers are designed to help clinicians navigate through the complex management of patients with CNS tumors. Several important principles guide surgical management and treatment with radiotherapy and systemic therapy for adults with brain tumors. The NCCN CNS Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding molecular profiling of gliomas.

UR - http://www.scopus.com/inward/record.url?scp=85146195028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85146195028&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2023.0002

DO - 10.6004/jnccn.2023.0002

M3 - Article

C2 - 36634606

AN - SCOPUS:85146195028

SN - 1540-1405

VL - 21

SP - 12

EP - 20

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 1

ER -